I hereby certify that this correspondence is being deposited with the U.S. 45 Postal Service as Express March III No. <u>EL8296450</u>, an an envelope addressed to: Component of Patents, Washington, DC 20231, on the date shown below.

Dated: March 20, 2002 Signature:

10/088875 JC13 Rec'd PCT/PTO 0 2 MAR 2002

Docket No.: NY-HUBR 1206-

US

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Hans Schuhbauer

Application No.: Not Yet Assigned

Group Art Unit: N/A

stoup the ome. 1471

Filed: herewith

Examiner: Not Yet Assigned

For:

RETARD FORM CONTAINING ALPHA-

LIPOIC ACID (DERIVATIVES)

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information

Application No.: Not Yet American

JC13 Rec'd POT/PTO 0 2 MAR 2002 Docket NY-HUBR 1206-US

as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0624, under Order No. NY-HUBR 1206-US. A duplicate copy of this paper is enclosed.

Dated: March 20, 2002

Respectfully submitted,

James R. Crawford

Registration No.: 39,155

FÜLBRIGHT & JAWORSKI L.L.P.

666 Fifth Avenue

New York, New York 10103

(212) 318-3000

(212) 318-3400 (Fax)

Attorneys for Applicant

9 Tay 3 This in 0 2 MAR 2002

PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	Not Yet Assigned	
11	<b>IFORMATION</b>	1 DI	SCLOSURE	Filing Date		
STATEMENT BY APPLICANT				First Named Inventor	Hans Schuhbauer	
				Art Unit	N/A	
(use as many sheets as necessary)				Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	NY-HUBR 1206-US	

s, Columns, Lines, Vhere Relevant
sages or Relevant
ocument Passages or Relev Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) MM-DD-Y		Applicant of Cited Document	Passages or Relevant Figures Appear	T <sup>6</sup>
	BA	EP-0 427 246-	05-15-1991	Asta Pharma		
	BB	EP-0 702 953-	03-27-1996	Asta Medica		
	BC	EU-0 560 092-	09-15-1993	Asta Medica		

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.